Boston Scientific Corporation vs Hut 8 Corp — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while Hut 8 Corp trades at $99.31 (market cap $11.07B). The key difference: Boston Scientific Corporation is far larger — about 6× Hut 8 Corp's market cap, and Hut 8 Corp is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | HUT | |
|---|---|---|
Market Cap | $66.37B | $11.07B |
Sector | Health | Technology |
52-Week High | $108.14 | $133.02 |
52-Week Low | $42.63 | $19.45 |
Enterprise Value | $75.94B | $11.33B |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
HUT trades at $99.17, down 2.98% today, with a bearish technical signal. The company shows strong revenue growth potential but deep losses, with a net income margin of -109.77% in 2025. Recent news highlights its pivot to AI infrastructure, securing $16.8 billion in contracted revenue and closing a $4.25 billion investment-grade bond for data center projects.
Outlook is mixed: analyst consensus is strongly bullish with a $138.89 price target, but high valuation ratios and persistent negative cash flow from operations pose risks. The stock's near-term direction hinges on Q2 2026 earnings results and execution of its infrastructure expansion.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →